GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atossa Therapeutics Inc (MEX:ATOS) » Definitions » Cyclically Adjusted Book per Share

Atossa Therapeutics (MEX:ATOS) Cyclically Adjusted Book per Share : MXN190.90 (As of Mar. 2025)


View and export this data going back to 2021. Start your Free Trial

What is Atossa Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Atossa Therapeutics's adjusted book value per share for the three months ended in Mar. 2025 was MXN10.346. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is MXN190.90 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Atossa Therapeutics's average Cyclically Adjusted Book Growth Rate was -59.30% per year. During the past 3 years, the average Cyclically Adjusted Book Growth Rate was -35.10% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was -20.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Atossa Therapeutics was -2.00% per year. The lowest was -35.10% per year. And the median was -14.00% per year.

As of today (2025-05-29), Atossa Therapeutics's current stock price is MXN16.00. Atossa Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was MXN190.90. Atossa Therapeutics's Cyclically Adjusted PB Ratio of today is 0.08.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Atossa Therapeutics was 0.10. The lowest was 0.00. And the median was 0.00.


Atossa Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Atossa Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atossa Therapeutics Cyclically Adjusted Book per Share Chart

Atossa Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 813.70 725.62 418.87 247.94

Atossa Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 348.00 320.84 246.69 247.94 190.90

Competitive Comparison of Atossa Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Atossa Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atossa Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atossa Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Atossa Therapeutics's Cyclically Adjusted PB Ratio falls into.


;
;

Atossa Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Atossa Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book= Book Value per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=10.346/134.9266*134.9266
=10.346

Current CPI (Mar. 2025) = 134.9266.

Atossa Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201506 1,279.093 100.684 1,714.114
201509 905.793 100.392 1,217.390
201512 355.492 99.792 480.651
201603 300.685 100.470 403.805
201606 202.586 101.688 268.805
201609 331.272 101.861 438.808
201612 202.060 101.863 267.647
201703 91.047 102.862 119.428
201706 60.628 103.349 79.152
201709 39.789 104.136 51.554
201712 51.387 104.011 66.661
201803 36.034 105.290 46.177
201806 54.695 106.317 69.413
201809 35.794 106.507 45.345
201812 29.568 105.998 37.638
201903 41.458 107.251 52.156
201906 36.928 108.070 46.105
201909 32.470 108.329 40.442
201912 27.174 108.420 33.817
202003 27.980 108.902 34.667
202006 20.775 108.767 25.772
202009 20.839 109.815 25.604
202012 11.366 109.897 13.955
202103 23.635 111.754 28.536
202106 22.775 114.631 26.807
202109 22.953 115.734 26.759
202112 22.379 117.630 25.670
202203 21.253 121.301 23.640
202206 20.695 125.017 22.335
202209 19.675 125.227 21.199
202212 18.163 125.222 19.571
202303 16.122 127.348 17.081
202306 14.213 128.729 14.897
202309 13.658 129.860 14.191
202312 12.329 129.419 12.854
202403 11.340 131.776 11.611
202406 11.678 132.554 11.887
202409 11.533 133.029 11.698
202412 11.541 133.157 11.694
202503 10.346 134.927 10.346

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Atossa Therapeutics  (MEX:ATOS) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Atossa Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=16.00/190.90
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Atossa Therapeutics was 0.10. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Atossa Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Atossa Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Atossa Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
10202 Fifth Avenue NE, Suite 200, Seattle, WA, USA, 98125
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Atossa Therapeutics Headlines

From GuruFocus